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OBJECTIVES: COPD cost of illness assessment and its dependence on GOLD stage 
or duration of hospital admission. METHODS: The sample consisted of 186 elderly 
COPD patients. Chest physicians conducted follow-up and ﬁ nancial data were 
obtained from administrative registry. Time horizon was one year and Health Insur-
ance Fund perspective was selected. Included clinical endpoints were disease exacerba-
tion and hospital admission. Economic data included all inpatient COPD-related 
medical goods and services consumption, and outpatient drug utilization. We excluded 
medical costs which did not arise from COPD. RESULTS: An average elderly COPD 
patient imposed c1745.41 of costs annually to the national health care budget. Severity 
grade (GOLD stage) and duration of all hospital admissions were signiﬁ cantly and 
directly correlated with overall cost. Expenses structure per year was: c14.54 outpa-
tient care, c126.97 inpatient drug consumption, c377.98 hospital admission (Intensive 
Care Unit admissions and specialist consultations included in daily price), c133.5 
imaging diagnostics, c111.43 laboratory analysis, c26.67 therapeutic interventions, 
c70.32 consumables, c884 outpatient drugs consumption. Most expenses originating 
from drug acquisition were due to antibiotics prescribed for curing infections and 
mucolitics and antihistamine drugs consumption. Average number of hospitalizations 
per person was 1.45 with a duration of 12.84 days. Fifteen persons deceased. Average 
number of outpatient visits was 2.71 per person. CONCLUSIONS: Overall burden 
of COPD is mostly driven by outpatient drug consumption and exacerbations leading 
to hospital admissions. Relative relevance of drug acquisition expenses in our country 
is higher than in high-income societies, because of still signiﬁ cantly lower human 
labour wages in the area. Pattern of diagnostic procedures requested and ATC drug 
classes consumed remains similar and comparable in most countries. More in-depth 
research of indirect COPD attributable costs e.g. lost productivity, absentism, prema-
ture death etc, will be needed in the future.
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OBJECTIVES: Ageing population implies greater demand of hospital services and 
consequent health care costs. This study aims to describe patterns of hospitalization 
and estimate hospitalization costs for aged patients in public hospitals in the city of 
Rio de Janeiro, Brazil. METHODS: Retrospective analysis of Rio de Janeiro hospital 
admissions for elderly people (aged ≥60 years) as reported in Brazilian Hospital 
Information System (SIH/DATASUS) database from January 1st to December 31st 
2007. The costs informed in the database represent federal reimbursement values for 
hospitalizations placed in public hospitals in the city. Admissions were categorized 
according to ICD-10 groups and age categories. RESULTS: 287,972 hospital admis-
sions were identiﬁ ed for all ages in the city in 2007 and 24.3% were for patients ≥60 
years (70,077). The ﬁ ve more common reasons for hospitalization were cardiovascular 
diseases (22.4%), cancer (17.5%), mental and cognitive disorders (11.2%), gastroin-
testinal (9.3%) and respiratory diseases (7.6%). The in-hospital mortality rate was 
14.76% for all causes. When disease groups were analyzed, infectious and respiratory 
diseases had the higher mortality rates (38.6% and 38.3%, respectively). The mean 
length of stay was 14.3 days and the average cost for elderly patients hospitalizations 
was 960,62 BRL. The total amount paid for hospitalization of elderly patients in 2007 
was 67,317,348 BRL, 30.7% of all hospitalization costs. CONCLUSIONS: The ﬁ nd-
ings showed the signiﬁ cant contribution of the elderly to public hospital expenditures 
with leading causes of admission including cardiovascular diseases, cancer and mental 
and cognitive disorders. Additionally, the higher in-hospital mortality rate was seen 
for preventable diseases. These results reinforce the need of prevention strategies 
among the elder population for targeted conditions.
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OBJECTIVES: To perform cost-beneﬁ t analysis of ﬂ uconazole for VC in Russia. 
METHODS: Willingness-to-pay (WTP) for treatment of vaginal candidiasis was 
assessed. 240 women took part in the survey. a special questionnaire was designed to 
reveal women’s preferable methods of antifungal drug application and WTP for ﬂ u-
conazole in comparison with other drugs. Women were proposed: 1) to chose the 
preferable method of drug application; 2) to chose the preferable drug among 4 
options with similar efﬁ cacy but different methods of application and price (no con-
crete drug names were mentioned, only prices and costs of treatment and application 
methods); and 3) to give the maximal affordable price for treating vaginal candidiasis. 
RESULTS: More than 60% of women preferred oral treatment once with the mean 
costs of therapy 350 rubles ($11) among 4 proposed alternatives. The median WTP 
for antifungal therapy was 500 rubles ($16) (range from 50 to 5000 rubles, $1.6–
161.0) that is less than real cost of treatment with original ﬂ uconazole preparation. 
The cost-beneﬁ t ratio (WTP/cost of treatment) was 1.30 (range 0.09–20.6). CON-
CLUSIONS: Fluconazole is a cost-beneﬁ t alternative for VC treatment.
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OBJECTIVES: Anemia is a common side effect observed in patients receiving myelo-
suppressive chemotherapy [1]. The purpose of this pharmacoeconomic analysis was 
to evaluate the cost-effectiveness of the long-acting erythropoiesis-stimulating agent 
(ESA) darbepoetin alfa (DA) 500 mcg once every 3 weeks (Q3W) and 150 mcg weekly 
(QW), and short-acting ESAs epoetin-alfa (EA) 40,000 IU QW, epoetin-beta (EB) 
30,000 IU QW and 3-times weekly (TIW) for the treatment of CIA. METHODS: A 
cost-consequence model was constructed using a decision-analysis tree. The treatment 
period considered was based on 12 weeks and was aligned with routine chemotherapy 
regimen administration. Model inputs included: medical treatment, outcomes, and 
health care service utilization from published clinical trials and summary of product 
characteristics recommendation. Effectiveness of therapeutic alternatives was deter-
mined by comparing hemoglobin response rates. Costs included direct medical 
costs(intervention drug, inpatient and outpatient) and transportation costs. Costs 
presented reﬂ ect 2010 data. The analysis was performed from the perspective of the 
Austrian health care system. RESULTS: The average expected direct costs per patient 
were c3,675 for DA Q3W, c3830 for DA QW, c4290 for EA QW, c4240 for EB QW 
and c4745 for EB TIW. Cost-savings associated with DA Q3W were 4% relative to 
DA QW, 14% to EA QW, 13% to EB QW and 23% to EB TIW. The cost per hemo-
globin response rate (therapeutic success) amounted to c5035 for DA Q3W, c5247 
for DA QW, c6309 for EA QW, c6235 for EB QW and c6977 for EB TIW. CON-
CLUSIONS: In the treatment of CIA among cancer patients in Austria, darbepoetin 
alfa Q3W and QW are projected to provide more efﬁ cient use of health care resources 
compared to alternative treatment strategies such as epoetin-alfa and epoetin-beta. [1] 
Ludwig et al. Eur J Cancer 2004;40:2293–306.
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OBJECTIVES: Estimate the clinical and economic outcomes of the surgical repair of 
anterior vaginal wall prolapse using Prolift® vs. colporrhaphy to assess its cost-
effectiveness under a third level hospital perspective in Mexico. METHODS: A multi-
state Markov model was developed to assess the evolution of a patient with anterior 
vaginal wall prolapse under a conventional surgical repair strategy (colporrhaphy) and 
a mesh grant (Prolift®) after 2, 4, 10 and 20 years. a specialist panel was conducted 
to collect current clinical practice, resource utilization and complication data. After 
the ﬁ rst surgical prolapse repair, the base-case patient could face two additional 
surgeries if prolapse relapsed. Two scenarios were modeled to compare the clinical 
and economic impact of Prolift® as second line treatment; the mesh grant was the 
assumed third line treatment for both scenarios. The effectiveness variable was the 
objective recurrence (failure) rate. Clinical data, transition probabilities and mortality 
rates were taken from published sources. Only direct medical costs were considered, 
and cost data was retrieved from IMSS ofﬁ cial cost list. The price of Prolift® was 
internally estimated. Results are expressed as 2010 inﬂ ation-adjusted Mexican pesos 
(MXN) and MXN/QALY for ICERs. a 4.5% discount rate was used for costs and 
outcomes. RESULTS: Total costs for year 1 were higher for the Prolift® strategy 
($75,688 vs. $74,544), but yielded an overall 22% complication reduction. For year 
2, total costs were lower for Prolift® ($81,675 vs. $104,007), yielding better outcomes 
(0.04 incremental QALYs), thus being a dominant strategy (−$528,682/QALY). For 
the following years, Prolift® showed to be a consistent cost-saving alternative vs. 
colporrhaphy: ICERs for years 4, 10 and 20 were −$273,598/QALY, −$29,942/QALY 
and −$1,212/QALY. CONCLUSIONS: Findings suggest Prolift® is a safe and cost-
effective alternative to treat anterior vaginal wall prolapse when compared to colpor-
rhaphy. Savings are due to lower failure and complication rates.
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OBJECTIVES: To estimate the impact of vaccination timing on the cost-effectiveness 
of seasonal inﬂ uenza vaccination in pregnancy for prevention of disease in women 
and infants under 6 months of age. METHODS: We constructed an open cohort 
